FDA Lauds St. Gallen's Findings On 10 Metrics For Ensuring Drug Quality

US FDA touts new evidence that high performance of pharmaceutical manufacturing sites on 10 quality maturity metrics correlates with robust pharmaceutical quality systems, operational excellence and good business. An FDA-funded study by St. Gallen also finds that low performance, on the other hand, correlates with manufacturing problems.

Big data analytics and business intelligence (BI) concept with chart and graph icons on a digital screen interface

An FDA-commissioned report on quality metrics sheds light on how a strong culture improves a pharmaceutical manufacturer’s quality system and ultimately its bottom line. Strong quality maturity or quality culture programs lead to robust pharmaceutical quality systems that can catch major defects early on.

The report also suggests that metrics be incorporated into firms’ operational excellence programs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America